TET2截短突变预示着母细胞性浆细胞样树突状细胞肿瘤的预后更差。 - Suppr

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

作者信息

Beird Hannah, Yin C Cameron, Khoury Joseph D, Pierce Sherry, Abbas Hussein A, Zhao Li, Skwarska Anna, Qazilbash Muzaffar, Konopleva Marina, Futreal P Andrew, Pemmaraju Naveen

机构信息

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.

Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Blood Adv. 2023 May 23;7(10):2000-2003. doi: 10.1182/bloodadvances.2022007879.

DOI:10.1182/bloodadvances.2022007879

PMID:36689729

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10188632/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b83a/10188632/372908003734/BLOODA_ADV-2022-007879-gr1.jpg

相似文献

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.TET2截短突变预示着母细胞性浆细胞样树突状细胞肿瘤的预后更差。

Blood Adv. 2023 May 23;7(10):2000-2003. doi: 10.1182/bloodadvances.2022007879.

Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.源自共同TET2突变起源的母细胞性浆细胞样树突状细胞肿瘤和慢性粒单核细胞白血病的不同克隆进化。

Leukemia. 2021 Nov;35(11):3299-3303. doi: 10.1038/s41375-021-01228-y. Epub 2021 Apr 8.

Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.弥漫性大 B 细胞淋巴瘤的分子特征：基因突变与表观遗传学。

Hematol Oncol Clin North Am. 2020 Jun;34(3):511-521. doi: 10.1016/j.hoc.2020.01.002. Epub 2020 Mar 4.

Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.伴有多种表观遗传修饰因子基因突变的母细胞性浆细胞样树突状细胞瘤：一例报告

J Int Med Res. 2021 Feb;49(2):300060520982667. doi: 10.1177/0300060520982667.

Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP.在TET2和ZRSR2突变的意义未明的克隆性血细胞减少症背景下发生的皮肤母细胞性浆细胞样树突状细胞肿瘤，继发于涉及CDK2NA/2NB和MTAP的体细胞拷贝数丢失。

Am J Hematol. 2020 Feb;95(2):E31-E34. doi: 10.1002/ajh.25675. Epub 2019 Dec 4.

Blastic Plasmacytoid Dendritic Cell Neoplasm: The Dermatologist's Perspective.原始细胞性浆细胞样树突细胞肿瘤：皮肤科医生的视角。

Hematol Oncol Clin North Am. 2020 Jun;34(3):501-509. doi: 10.1016/j.hoc.2020.01.001. Epub 2020 Mar 20.

New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis.

J Thromb Haemost. 2010 May;8(5):1142-4. doi: 10.1111/j.1538-7836.2010.03810.x. Epub 2010 Feb 12.

TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.TET2 突变、骨髓增生异常特征和独特的免疫表型可用于特征性诊断骨髓中的原始浆细胞样树突状细胞瘤。

Am J Hematol. 2013 Dec;88(12):1055-61. doi: 10.1002/ajh.23567. Epub 2013 Sep 30.

Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm.在母细胞性浆细胞样树突状细胞肿瘤中未检测到细胞质核磷蛋白。

Haematologica. 2009 Feb;94(2):285-8. doi: 10.3324/haematol.13855. Epub 2008 Dec 9.

TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.在母细胞性浆细胞样树突状细胞瘤中经常观察到TET2和TP53突变。

Br J Haematol. 2011 May;153(3):413-6. doi: 10.1111/j.1365-2141.2010.08556.x. Epub 2011 Jan 31.

引用本文的文献

Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.母细胞性浆细胞样树突状细胞肿瘤的遗传学特征：单机构经验

Oncotarget. 2025 Jun 17;16:495-507. doi: 10.18632/oncotarget.28742.

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN.维奈托克与去甲基化药物用于复发型母细胞性浆细胞样树突状细胞肿瘤的前瞻性临床试验。

Blood Neoplasia. 2025 Mar 3;2(2):100086. doi: 10.1016/j.bneo.2025.100086. eCollection 2025 May.

Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.小儿原始浆细胞样树突状细胞瘤：一例报告

Clin Pathol. 2024 Dec 16;17:2632010X241304564. doi: 10.1177/2632010X241304564. eCollection 2024 Jan-Dec.

BPDCN: state of the art.母细胞性浆细胞样树突状细胞肿瘤：最新进展

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):279-286. doi: 10.1182/hematology.2024000553.

Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival.成人 BPDCN 中的器官受累与日照史、TET2 和 RAS 突变及生存有关。

Blood Adv. 2024 Jun 11;8(11):2803-2812. doi: 10.1182/bloodadvances.2024012797.

Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis.皮肤原始浆细胞样树突状细胞肿瘤与源自克隆性造血的骨髓增生异常综合征的巧合。

Blood Cancer J. 2023 Aug 9;13(1):119. doi: 10.1038/s41408-023-00893-9.

本文引用的文献

The burden of rare protein-truncating genetic variants on human lifespan.罕见蛋白截断基因突变对人类寿命的影响。

Nat Aging. 2022 Apr;2(4):289-294. doi: 10.1038/s43587-022-00182-3. Epub 2022 Mar 3.

Biallelic mutations and canonical mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature.双等位基因突变和典型突变在母细胞性浆细胞样树突状细胞肿瘤（BPDCN）中很常见且同时出现：一项机构经验及文献综述

EJHaem. 2023 Jan 4;4(1):236-240. doi: 10.1002/jha2.617. eCollection 2023 Feb.

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.Tagraxofusp 治疗原始浆细胞样树突状细胞瘤患者的长期获益。

J Clin Oncol. 2022 Sep 10;40(26):3032-3036. doi: 10.1200/JCO.22.00034. Epub 2022 Jul 12.

Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.骨髓克隆性造血在原始浆细胞样树突状细胞瘤中高度普遍存在，并且在老年患者中经常具有克隆起源。

Leukemia. 2022 May;36(5):1343-1350. doi: 10.1038/s41375-022-01538-9. Epub 2022 Mar 12.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.初治 HCVAD 方案治疗原始浆细胞样树突状细胞瘤患者的特征和结局。

Blood Adv. 2022 May 24;6(10):3027-3035. doi: 10.1182/bloodadvances.2021006645.

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm.母细胞样浆细胞样树突状细胞瘤的综合临床基因型-表型特征

Cancers (Basel). 2021 Nov 23;13(23):5888. doi: 10.3390/cancers13235888.

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.维奈托克与低甲基化药物用于老年/身体状况不佳的浆细胞样树突状细胞肿瘤患者的治疗

Am J Hematol. 2022 Feb 1;97(2):E62-E67. doi: 10.1002/ajh.26417. Epub 2021 Nov 29.

Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).异基因造血细胞移植治疗原始浆细胞样树突状细胞瘤（BPDCN）患者。

Bone Marrow Transplant. 2022 Jan;57(1):51-56. doi: 10.1038/s41409-021-01478-5. Epub 2021 Oct 11.

Sex-Biased Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.髓系恶性肿瘤中的性别偏向性突变会损害浆细胞样树突状细胞的激活和凋亡。

Cancer Discov. 2022 Feb;12(2):522-541. doi: 10.1158/2159-8290.CD-20-1513. Epub 2021 Oct 6.

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm.中枢神经系统受累于母细胞性浆细胞样树突状细胞肿瘤。

Blood. 2021 Oct 14;138(15):1373-1377. doi: 10.1182/blood.2021011817.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献